Pharmacology, efficacy and safety of oral phosphate binders (Q34213752)

31 July 2017

1 reference

title

Pharmacology, efficacy and safety of oral phosphate binders (English)

1 reference

31 July 2017

1 reference

1

Alastair J Hutchison

1 reference

31 July 2017

3

Paul E C Brenchley

1 reference

31 July 2017

Craig P Smith

2

1 reference

31 July 2017

language of work or name

English

0 references

publication date

6 September 2011

1 reference

Nature Reviews Nephrology

31 July 2017

published in

1 reference

31 July 2017

volume

7

1 reference

31 July 2017

issue

10

1 reference

31 July 2017

page(s)

578-589

1 reference

Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

The mechanism of phosphorus as a cardiovascular risk factor in CKD

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Pathophysiology of calcium and phosphate metabolism impairment in chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Renal osteodystrophy, phosphate homeostasis, and vascular calcification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Phosphorus homeostasis in normal health and in chronic kidney disease patients with special emphasis on dietary phosphorus intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Recent advances in the rapidly evolving field of fibroblast growth factor 23 in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Phosphorus balance with daily dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

FGF-23 in patients with end-stage renal disease on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

FGF23-parathyroid interaction: implications in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Severely reduced production of klotho in human chronic renal failure kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Protein carbamylation links inflammation, smoking, uremia and atherogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Phosphorus binders and survival on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Aluminium poisoning: dialysis encephalopathy, osteomalacia, and anaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

21 January 2018

Aluminum as a toxicant

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Frequency of elevated serum aluminum levels in adult dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Oral Phosphate Binders in Patients with Kidney Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Reduced risk of hypercalcemia for hemodialysis patients by administering calcitriol at night

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Influence of pH on in vitro disintegration of phosphate binders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Serum magnesium level and arterial calcification in end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Vascular Smooth Muscle Cell Differentiation to an Osteogenic Phenotype Involves TRPM7 Modulation by Magnesium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Dietary magnesium, not calcium, prevents vascular calcification in a mouse model for pseudoxanthoma elasticum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Clinical pharmacokinetics of the phosphate binder lanthanum carbonate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Lanthanum: a safe phosphate binder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Lanthanum carbonate for the treatment of hyperphosphataemia in renal failure and dialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Sevelamer hydrochloride (Renagel), a nonabsorbed phosphate-binding polymer, does not interfere with digoxin or warfarin pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Sevelamer, a phosphate-binding polymer, is a non-absorbed compound

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Sevelamer hydrochloride (Renagel), a phosphate-binding polymer, does not alter the pharmacokinetics of two commonly used antihypertensives in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Iron-magnesium hydroxycarbonate (fermagate): a novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyperphosphataemia: a double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Sevelamer versus calcium-based phosphate binders in chronic kidney disease: what should we conclude from the evidence to date?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Patients' satisfaction with information about phosphate-binding medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Lower gastrointestinal bleeding: association with Sevelamer use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

The role of magnesium binders in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Substitution of aluminium salts by magnesium salts in control of dialysis hyperphosphataemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Long-term effects of magnesium carbonate on coronary artery calcification and bone mineral density in hemodialysis patients: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Accumulation of metals and minerals from phosphate binders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Nicotinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Nicotinamide suppresses hyperphosphatemia in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Safety of high-dose nicotinamide: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Characterization of a murine type II sodium-phosphate cotransporter expressed in mammalian small intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Targeted deletion of the tybe IIb Na( )-dependent Pi-co-transporter, NaPi-IIb, results in early embryonic lethality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Intestinal npt2b plays a major role in phosphate absorption and homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Systemic lanthanum is excreted in the bile of rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Calcium-based phosphate binders are appropriate in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Phosphorus additives in food and their effect in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Fibroblast Growth Factor 23 (FGF23) Predicts Progression of Chronic Kidney Disease: The Mild to Moderate Kidney Disease (MMKD) Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

A plain X-ray vascular calcification score is associated with arterial stiffness and mortality in dialysis patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

A simple vascular calcification score predicts cardiovascular risk in haemodialysis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Biochemical and hematological changes in low-level aluminum intoxication

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Dialysis encephalopathy secondary to aluminum toxicity, diagnosed by bone biopsy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Calcium acetate versus calcium carbonate as phosphate-binding agents in chronic haemodialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Calcium alginate versus aluminum hydroxide in patients on hemodialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Calcium ketoglutarate versus calcium acetate for treatment of hyperphosphataemia in patients on maintenance haemodialysis: a cross-over study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Magnesium studies in hemodialysis patients before and after treatment with low dialysate magnesium

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Hypercalcaemia, hypermagnesaemia, hyperphosphataemia and hyperaluminaemia in CAPD: improvement in serum biochemistry by reduction in dialysate calcium and magnesium concentrations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

RnaGel(R), a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Effect of RenaGel, a non-absorbable, cross-linked, polymeric phosphate binder, on urinary phosphorus excretion in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

The case against calcium-based phosphate binders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Phosphate binders: hold the calcium?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Serum magnesium and parathyroid hormone levels in dialysis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Enlightenment on liver lanthanum exposure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Efficacy and safety of SBR759, a new iron-based phosphate binder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Luminal fructose inhibits rat intestinal sodium-phosphate cotransporter gene expression and phosphate uptake

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Chromosomal localization of two human genes involved in phosphate homeostasis: the type IIb sodium-phosphate cotransporter and stanniocalcin-2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Intestinal phosphate absorption and the effect of vitamin D: a comparison of rats with mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038/NRNEPH.2011.112

Relationship between serum magnesium, parathyroid hormone, and vascular calcification in patients on dialysis: a literature review

31 March 2020

1 reference

12 December 2020

Aluminum deposition in the bone of patients with chronic renal failure--detection of aluminum accumulation without signs of aluminum toxicity in bone using acid solochrome azurine

1 reference

12 December 2020

Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysis.

1 reference

12 December 2020

Alternative phosphate binders in dialysis patients: calcium carbonate

1 reference

12 December 2020

Sevelamer: constipation and occlusion. Complications, sometimes fatal

1 reference

12 December 2020

The parathyroid is a target organ for FGF23 in rats

1 reference

12 December 2020

Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study

1 reference

12 December 2020

Effect of histamine H2-receptor antagonist on the phosphorus-binding abilities of calcium carbonate and calcium lactate in hemodialysis patients

1 reference

12 December 2020

The beneficial effect of ketoacids on serum phosphate and parathyroid hormone in patients with chronic uremia.

1 reference

12 December 2020

Calcium alginate, an aluminum-free phosphate binder, in patients on CAPD

1 reference

12 December 2020

A comparative study of 2 new phosphate binders (sevelamer and lanthanum carbonate) in routine clinical practice

1 reference

12 December 2020

Serum phosphate control: what about calcium salts of keto-amino acids?

1 reference

12 December 2020

Phosphorus binders: preferences of patients on haemodialysis and its impact on treatment compliance and phosphorus control

1 reference

12 December 2020

Challenge of phosphorus control in hemodialysis patients: a problem of adherence?

1 reference

12 December 2020

KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).

1 reference

12 December 2020

Correlation of serum magnesium with serum parathormone levels in patients on regular hemodialysis

1 reference

12 December 2020

Calcium and magnesium mass transfer in peritoneal dialysis patients using 1.25 mmol/L calcium, 0.25 mmol/L magnesium dialysis fluid

1 reference

12 December 2020

The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEPH.2011.112

1 reference

Dimensions Publication ID

31 July 2017

1017261440

0 references

1 reference